Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Massachusetts General Hospital
Novartis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Faron Pharmaceuticals Ltd
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
University of Utah
Center for International Blood and Marrow Transplant Research
University of Southern California
City of Hope Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Novartis
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
City of Hope Medical Center
University of Alabama at Birmingham
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Foghorn Therapeutics Inc.
Eli Lilly and Company
City of Hope Medical Center
City of Hope Medical Center
Treadwell Therapeutics, Inc
Otsuka Australia Pharmaceutical Pty Ltd
AbbVie
Rigshospitalet, Denmark
Asan Medical Center